Regulus Therapeutics Inc. logo

Regulus Therapeutics Inc.

NASDAQ:RGLS

Overview | Financials
Company Name Regulus Therapeutics Inc.
Symbol RGLS
Currency USD
Price 1.62
Market Cap 106,054,758
Dividend Yield 0%
52-week-range 1.08 - 3.79
Industry Biotechnology
Sector Healthcare
CEO Mr. Joseph P. Hagan M.B.A.
Website https://www.regulusrx.com

An error occurred while fetching data.

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport

Related Stocks

Microbot Medical Inc. logo

Microbot Medical Inc.

MBOT

0.925 USD

Psychemedics Corporation logo

Psychemedics Corporation

PMD

2.33 USD

Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc.

TARA

1.92 USD

FSD Pharma Inc. logo

FSD Pharma Inc.

HUGE

0.09 USD

Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

9.18 USD

Financials

Numbers are in millions USD

Numbers are in millions USD